Categories: News

Sarepta Therapeutics to Announce Second Quarter 2022 Financial Results and Recent Corporate Developments on August 2, 2022

CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2022 financial results after the Nasdaq Global Market closes on Tuesday, August 2, 2022. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its second quarter 2022 financial results and to provide a corporate update.

The event will be webcast live under the investor relations section of Sarepta’s website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.

About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

Internet Posting of Information
We routinely post information that may be important to investors in the ‘For Investors’ section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com

Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com

Staff

Recent Posts

Sona’s Therapy Shows Significant Preclinical Efficacy in Second Cancer

Halifax, Nova Scotia--(Newsfile Corp. - June 20, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB:…

50 mins ago

Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer

SAN DIEGO--(BUSINESS WIRE)--#TandemDiabetes--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology…

2 hours ago

BSIM Healthcare Services Selects Innovaccer’s Healthcare AI Platform as Foundation for Scaling Value-Based Care Model

Leveraging Innovaccer's healthcare AI platform, BSIM Healthcare Services aims to improve care delivery for underserved…

2 hours ago

EndoSound Vision System™ Granted Transitional CMS Pass-Through Code

PORTLAND, Ore.--(BUSINESS WIRE)--EndoSound®, Inc., is thrilled to announce that the Centers for Medicare & Medicaid…

2 hours ago

Canadian Institute of Actuaries Welcomes New President and Board Members

Ottawa, Ontario--(Newsfile Corp. - June 20, 2024) - The Canadian Institute of Actuaries (CIA) has…

2 hours ago

NervGen Pharma to Present at the 2nd Annual Spinal Cord Injury Investor Symposium

Vancouver, British Columbia--(Newsfile Corp. - June 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB:…

2 hours ago